HCC - Hepatocellular Carcinoma: Clinical Trials

84 trials for HCC - Hepatocellular Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 recruiting, 24 not yet recruiting, 8 completed, 6 active not recruiting. 32 Phase 2, 17 Not applicable, 9 Phase 1, 3 Phase 3, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 232Recruiting 15, Not yet recruiting 13, Active not recruiting 3, Completed 1
Not applicable17Not yet recruiting 6, Recruiting 5, Completed 3, Active not recruiting 1, Enrolling by invitation 1, Unknown 1
Phase 19Recruiting 5, Not yet recruiting 3, Active not recruiting 1
Phase 33Recruiting 2, Completed 1
Phase 42Not yet recruiting 1, Recruiting 1
Early Phase 11Suspended 1

Follow HCC - Hepatocellular Carcinoma: new trials by email Literature Review of HCC - Hepatocellular Carcinoma trials Research Report on HCC - Hepatocellular Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingMedSIR442027-03-012026-11-04
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology352026-10-012026-09-15
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2882026-09-302026-08-12
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib - HCC - Hepatocellular Carcinoma
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital202026-09-012026-09-03
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
RecruitingNorthern Jiangsu People's Hospital302026-08-022026-09-10
Real-world Insight Into Systemic Therapies for HCC: Single-center Study
HCC - Hepatocellular Carcinoma
RecruitingMansoura University10002026-08-012026-09-10
Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation
Stereotactic body radiation therapy (SBRT) in addition to TACE prior to liver transplantation, The patients will receive two procedures of TACE prior to liver transplantation - HCC - Hepatocellular Carcinoma
Not applicableRecruitingAIO-Studien-gGmbH442026-07-282026-11-09
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
IMM2510, IMM27M - HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingImmuneOnco Biopharmaceuticals (Shanghai) Inc.502026-07-232026-07-07
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy (SBRT), QL1706 - HCC - Hepatocellular Carcinoma
Phase 4Not yet recruitingHebei Medical University Fourth Hospital362026-07-012026-06-25
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
eparlitozoviril, Control group - HCC - Hepatocellular Carcinoma
Phase 2Active not recruitingTianjin Medical University Cancer Institute and Hospital602026-06-122026-06-18
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Tislelizumab, Lenvatinib - HCC - Hepatocellular Carcinoma
Phase 3RecruitingTianjin Medical University Cancer Institute and Hospital1982026-06-092026-08-05
Social Determinants of Health HCC Trial
Social Determinants of Health Program, Patient Navigation - HCC - Hepatocellular Carcinoma
Not applicableNot yet recruitingUniversity of Southern California752026-06-012026-05-05
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Iparomlimab and Tuvonralimab - HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302026-05-302026-04-07
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC - HCC - Hepatocellular Carcinoma
Not applicableNot yet recruitingHenan Cancer Hospital2082026-05-252026-06-01
The DoHAICs Study Expansion Phase
Donafenib, sintilimab, HAIC - HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital902026-05-202026-05-13
Defining the Ablative Dose for Y-90 TARE
Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres - HCC - Hepatocellular Carcinoma
Phase 2RecruitingNorthwestern University302026-05-152026-09-15
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Firsekibart + Tislelizumab + Lenvatinib - HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
Not applicableNot yet recruitingTongji Hospital252026-05-012026-04-17
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tislelizumab, Lenvatinib - HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital602026-04-302026-04-09
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
Liver-in-cube testing - HCC - Hepatocellular Carcinoma
RecruitingThe University of Hong Kong202026-04-132026-09-24

Showing 20 of 84. Sign in to see all of them.

Narrower conditions

Carcinoma, Hepatocellular (84)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Neoplasms (5)  ·  Melanoma (4)  ·  Colorectal Neoplasms (3)  ·  Endometrial Neoplasms (3)  ·  Fibrosis (3)  ·  Liver Neoplasms (3)  ·  Diabetes Mellitus (2)  ·  Liver Cirrhosis (2)  ·  Pancreatic Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Renal Cell (1)  ·  Cholangiocarcinoma (1)  ·  Fatty Liver (1)

Broader conditions

Adenocarcinoma (84)  ·  Carcinoma (84)  ·  Digestive System Diseases (84)  ·  Digestive System Neoplasms (84)  ·  Liver Diseases (84)  ·  Neoplasms by Histologic Type (84)  ·  Neoplasms by Site (84)  ·  Neoplasms, Glandular and Epithelial (84)  ·  Liver Neoplasms (81)  ·  Neoplasms (79)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Pathologic Processes (7)  ·  Lung Diseases (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Neoplasms (6)

Interventions

lenvatinib (9)  ·  tislelizumab (7)  ·  Bevacizumab (5)  ·  atezolizumab (5)  ·  sintilimab (5)  ·  Radiosurgery (4)  ·  durvalumab (3)  ·  tremelimumab (3)  ·  Immunotherapy (2)  ·  Radiotherapy (2)  ·  apatinib (2)  ·  camrelizumab (2)  ·  donafenib (2)  ·  pembrolizumab (2)  ·  Amino Acids, Branched-Chain (1)

Sponsors

Tianjin Medical University Cancer Institute and Hospital (7)  ·  IRCCS Azienda Ospedaliero-Universitaria di Bologna (3)  ·  Tongji Hospital (3)  ·  Zhongda Hospital (3)  ·  Beijing Tsinghua Chang Gung Hospital (2)  ·  Chang Gung Memorial Hospital (2)  ·  Chinese University of Hong Kong (2)  ·  Henan Cancer Hospital (2)  ·  Mansoura University (2)  ·  Northern Jiangsu People's Hospital (2)  ·  Shanghai Zhongshan Hospital (2)  ·  The University of Hong Kong (2)  ·  West China Hospital (2)  ·  AIO-Studien-gGmbH (1)  ·  Ain Shams University (1)

Countries

China (36)  ·  Egypt (4)  ·  Hong Kong (4)  ·  Italy (4)  ·  France (3)  ·  Taiwan (3)  ·  United States (3)  ·  Germany (2)  ·  Vietnam (2)  ·  Canada (1)  ·  Netherlands (1)  ·  Pakistan (1)  ·  Poland (1)  ·  Turkey (Türkiye) (1)

Top investigators

Haibo Shao (2)  ·  Ali M Hussein, PhD (1)  ·  Chuan Pang (1)  ·  Cristina Mosconi, MD (1)  ·  Fatih Selcukbiricik, MD (1)  ·  Gerald Prager, MD (1)  ·  Guo-Qing Jiang (1)  ·  Hao Feng, Ph.D.,MD (1)  ·  Hongxia Wang, Doctorate (1)  ·  Jimmy CT Lai, MB ChB (1)  ·  Li Bing, PhD. (1)  ·  Michael T Dill, PhD (1)

Results publications

PMID 11858978, PMID 12806613, PMID 15043519, PMID 21874260, PMID 30082086, PMID 31974491, PMID 31989907, PMID 33334813, PMID 34087115, PMID 34256416, PMID 34706232, PMID 34801630, PMID 35114133, PMID 35294089, PMID 36753026, PMID 36997828, PMID 37059069, PMID 37099632, PMID 37316719, PMID 37731001, PMID 38039993, PMID 38305472, PMID 38453934, PMID 38678378, PMID 38959326, PMID 39148179, PMID 39801235, PMID 39825376, PMID 39915765, PMID 40930561, PMID 40930564, PMID 41357510, PMID 42185926, PMID 42330996, PMID 42486514